Literature DB >> 20827279

From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation.

Ayhan A Zia1, German Kamalov, Kevin P Newman, Jesse E McGee, Syamal K Bhattacharya, Robert A Ahokas, Yao Sun, Ivan C Gerling, Karl T Weber.   

Abstract

Inappropriately (relative to dietary Na(+)) elevated plasma aldosterone concentrations (PAC), or aldosteronism, have been incriminated in both the appearance of the cardiometabolic syndrome (CMS) and its progressive nature. The deleterious dual consequences of elevated PAC and dietary Na(+) have been linked to several components of the CMS, including salt-sensitive hypertension. Moreover, their adverse consequences are considered to be synergistic, culminating in a pro-oxidant phenotype with oxidative injury involving the heart and systemic tissues, including peripheral blood mononuclear cells (PBMC). Our experimental studies in rats receiving aldosterone/salt treatment have identified a common pathogenic event that links aldosteronism to the induction of oxidative stress. Herein, we review these findings and the important role of excessive intracellular Ca(2+) accumulation (EICA), or intracellular Ca(2+) overloading, which occurs in the heart and PBMC, leading to, respectively, cardiomyocyte necrosis with a replacement fibrosis and an immunostimulatory state with consequent coronary vasculopathy. The origin of EICA is based on elevations in plasma parathyroid hormone, which are integral to the genesis of secondary hyperparathyroidism that accompanies aldosteronism and occurs in response to plasma-ionized hypocalcemia and hypomagnesemia whose appearance is the consequence of marked urinary and fecal excretory losses of Ca(2+) and Mg(2+). In addition, we found intracellular Ca(2+) overloading to be intrinsically coupled to a dyshomeostasis of intracellular Zn(2+), which together regulate the redox state of cardiac myocytes and mitochondria via the induction of oxidative stress and generation of antioxidant defenses, respectively. To validate our hypothesis, a series of site-directed, sequential pharmacological and/or nutriceutical interventions targeted along cellular-molecular cascades were carried out to either block downstream events leading to the pro-oxidant phenotype or to enhance antioxidant defenses. In each case, the interventions were found to be cardioprotective. These cumulative salutary responses raise the prospect that pharmacological agents and nutriceuticals capable of influencing extra- and intracellular Ca(2+) and Zn(2+) equilibrium could prevent adverse cardiac remodeling and thereby enhance the management of aldosteronism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20827279     DOI: 10.1038/hr.2010.159

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  13 in total

1.  Evaluation of left ventricle functions by tissue Doppler, strain, and strain rate echocardiography in patients with primary hyperparathyroidism.

Authors:  Didem Ozdemir; Gulhan Yuksel Kalkan; Nihal Akar Bayram; Eda Demir Onal; Reyhan Ersoy; Engin Bozkurt; Bekir Cakir
Journal:  Endocrine       Date:  2014-03-28       Impact factor: 3.633

2.  Mineralocorticoid receptor activation is crucial in the signalling pathway leading to the Anrep effect.

Authors:  Claudia I Caldiz; Romina G Díaz; Mariela B Nolly; Gladys E Chiappe de Cingolani; Irene L Ennis; Horacio E Cingolani; Néstor G Pérez
Journal:  J Physiol       Date:  2011-12-15       Impact factor: 5.182

Review 3.  Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives.

Authors:  Barbara Altieri; Giovanna Muscogiuri; Stavroula A Paschou; Andromachi Vryonidou; Silvia Della Casa; Alfredo Pontecorvi; Martin Fassnacht; Cristina L Ronchi; John Newell-Price
Journal:  Endocrine       Date:  2018-08-02       Impact factor: 3.633

Review 4.  The Potential Role of Aldosterone-Producing Cell Clusters in Adrenal Disease.

Authors:  Jung Soo Lim; William E Rainey
Journal:  Horm Metab Res       Date:  2020-03-30       Impact factor: 2.936

5.  Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial.

Authors:  Andreas Tomaschitz; Astrid Fahrleitner-Pammer; Burkert Pieske; Nicolas Verheyen; Karin Amrein; Eberhard Ritz; Katharina Kienreich; Jörg H Horina; Albrecht Schmidt; Elisabeth Kraigher-Krainer; Caterina Colantonio; Andreas Meinitzer; Stefan Pilz
Journal:  BMC Endocr Disord       Date:  2012-09-13       Impact factor: 2.763

6.  Hyperparathyroidism in patients with overt and mild primary aldosteronism.

Authors:  Christos Gravvanis; Labrini Papanastasiou; Spiridoula Glycofridi; Nikos Voulgaris; Ernestini Tyfoxylou; Kounadi Theodora; George Piaditis; Αthina Markou
Journal:  Hormones (Athens)       Date:  2021-09-15       Impact factor: 2.885

7.  Cardiac Dysfunction in Association with Increased Inflammatory Markers in Primary Aldosteronism.

Authors:  Jung Soo Lim; Sungha Park; Sung Il Park; Young Taik Oh; Eunhee Choi; Jang Young Kim; Yumie Rhee
Journal:  Endocrinol Metab (Seoul)       Date:  2016-11-03

8.  Relationship Between Carbohydrate Antigen 125 and Coronary Artery Calcification in Patients without Known Coronary Artery Disease.

Authors:  Kun Fu; Hua-Dong Liu; KuerBanJiang MaMuTi; Dong-Nan Hu; Peng Hao
Journal:  Med Sci Monit       Date:  2018-05-07

Review 9.  Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease.

Authors:  Stefania Gorini; Vincenzo Marzolla; Caterina Mammi; Andrea Armani; Massimiliano Caprio
Journal:  Biomolecules       Date:  2018-09-18

10.  Effects of Altered Calcium Metabolism on Cardiac Parameters in Primary Aldosteronism.

Authors:  Jung Soo Lim; Namki Hong; Sungha Park; Sung Il Park; Young Taik Oh; Min Heui Yu; Pil Yong Lim; Yumie Rhee
Journal:  Endocrinol Metab (Seoul)       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.